{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:54:58Z","timestamp":1790895298867,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T00:00:00Z","timestamp":1724025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T00:00:00Z","timestamp":1724025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"AbbVie"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"DOI":"10.1186\/s10194-024-01834-y","type":"journal-article","created":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T08:02:43Z","timestamp":1724054563000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Characterizing barriers to care in migraine: multicountry results from the Chronic Migraine Epidemiology and Outcomes \u2013 International (CaMEO-I) study"],"prefix":"10.1186","volume":"25","author":[{"given":"Michel","family":"Lanteri-Minet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Leroux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaza","family":"Katsarava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Lipton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumihiko","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjit","family":"Matharu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Fanning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aubrey","family":"Manack Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Sommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Seminerio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn C.","family":"Buse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,19]]},"reference":[{"key":"1834_CR1","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","volume":"390","author":"GBD 2016 Disease and Injury Incidence and Prevalence Collaborators","year":"2017","unstructured":"GBD 2016 Disease and Injury Incidence and Prevalence Collaborators (2017) Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990\u20132016: a systematic analysis for the global burden of Disease Study 2016. Lancet 390:1211\u20131259","journal-title":"Lancet"},{"key":"1834_CR2","unstructured":"(2016) Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990\u20132015: a systematic analysis for the global burden of Disease Study 2015. Lancet 388:1545\u20131602"},{"key":"1834_CR3","first-page":"19","volume":"258","author":"S Miller","year":"2014","unstructured":"Miller S, Matharu MS (2014) Migraine is underdiagnosed and undertreated. Practitioner 258:19\u201324","journal-title":"Practitioner"},{"key":"1834_CR4","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/head.14709","volume":"64","author":"F Cohen","year":"2024","unstructured":"Cohen F, Lipton RB (2024) Prevalence and burden of migraine in the United States: a systematic review. Headache 64:516\u2013532","journal-title":"Headache"},{"key":"1834_CR5","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s10194-023-01699-7","volume":"24","author":"B Raffaelli","year":"2023","unstructured":"Raffaelli B, Rubio-Beltr\u00e1n E, Cho SJ, De Icco R, Labastida-Ramirez A, Onan D et al (2023) Health equity, care access and quality in headache\u2014part 2. J Headache Pain 24:167","journal-title":"J Headache Pain"},{"key":"1834_CR6","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/head.14259","volume":"62","author":"RB Lipton","year":"2022","unstructured":"Lipton RB, Nicholson RA, Reed ML, Araujo AB, Jaffe DH, Faries DE et al (2022) Diagnosis, consultation, treatment, and impact of migraine in the US: results of the OVERCOME (US) study. Headache 62:122\u2013140","journal-title":"Headache"},{"key":"1834_CR7","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.mayocp.2019.11.025","volume":"95","author":"S Hutchinson","year":"2020","unstructured":"Hutchinson S, Lipton RB, Ailani J, Reed ML, Fanning KM, Manack Adams A et al (2020) Characterization of acute prescription migraine medication use: results from the CaMEO study. Mayo Clin Proc 95:709\u2013718","journal-title":"Mayo Clin Proc"},{"key":"1834_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/03331024231189112","volume":"43","author":"A Manack Adams","year":"2023","unstructured":"Manack Adams A, Buse DC, Leroux E, Lanteri-Minet M, Sakai F, Matharu M et al (2023) Chronic migraine epidemiology and outcomes\u2013international (CaMEO-I) study: methods and multi-country baseline findings for diagnosis rates and care. Cephalalgia 43:1\u201313","journal-title":"Cephalalgia"},{"key":"1834_CR9","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1111\/head.13407","volume":"58","author":"RB Lipton","year":"2018","unstructured":"Lipton RB, Munjal S, Alam A, Buse DC, Fanning KM, Reed ML et al (2018) Migraine in America symptoms and treatment (MAST) study: baseline study methods, treatment patterns, and gender differences. Headache 58:1408\u20131426","journal-title":"Headache"},{"key":"1834_CR10","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1212\/01.wnl.0000252808.97649.21","volume":"68","author":"RB Lipton","year":"2007","unstructured":"Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF (2007) Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 68:343\u2013349","journal-title":"Neurology"},{"key":"1834_CR11","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/head.14103","volume":"61","author":"DC Buse","year":"2021","unstructured":"Buse DC, Armand CE, Charleston Lt, Reed ML, Fanning KM, Adams AM et al (2021) Barriers to care in episodic and chronic migraine: results from the chronic migraine epidemiology and outcomes study. Headache 61:628\u2013641","journal-title":"Headache"},{"key":"1834_CR12","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1056\/NEJMoa2035908","volume":"385","author":"J Ailani","year":"2021","unstructured":"Ailani J, Lipton RB, Goadsby PJ, Guo H, Miceli R, Severt L et al (2021) Atogepant for the preventive treatment of migraine. N Engl J Med 385:695\u2013706","journal-title":"N Engl J Med"},{"key":"1834_CR13","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1212\/WNL.53.5.988","volume":"53","author":"WF Stewart","year":"1999","unstructured":"Stewart WF, Lipton RB, Whyte J, Dowson A, Kolodner K, Liberman JN et al (1999) An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score. Neurology 53:988\u2013994","journal-title":"Neurology"},{"key":"1834_CR14","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1046\/j.1526-4610.2003.03069.x","volume":"43","author":"M Iigaya","year":"2003","unstructured":"Iigaya M, Sakai F, Kolodner KB, Lipton RB, Stewart WF (2003) Reliability and validity of the Japanese Migraine Disability Assessment (MIDAS) Questionnaire. Headache 43:343\u2013352","journal-title":"Headache"},{"key":"1834_CR15","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/j.1468-2982.2007.01461.x","volume":"28","author":"E Magnoux","year":"2008","unstructured":"Magnoux E, Freeman MA, Zlotnik G (2008) MIDAS and HIT-6 French translation: reliability and correlation between tests. Cephalalgia 28:26\u201334","journal-title":"Cephalalgia"},{"key":"1834_CR16","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12955-018-0871-5","volume":"16","author":"T Benz","year":"2018","unstructured":"Benz T, Lehmann S, Gantenbein AR, Sandor PS, Stewart WF, Elfering A et al (2018) Translation, cross-cultural adaptation and reliability of the German version of the migraine disability assessment (MIDAS) questionnaire. Health Qual Life Outcomes 16:42","journal-title":"Health Qual Life Outcomes"},{"key":"1834_CR17","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41582-021-00509-5","volume":"17","author":"AK Eigenbrodt","year":"2021","unstructured":"Eigenbrodt AK, Ashina H, Khan S, Diener HC, Mitsikostas DD, Sinclair AJ et al (2021) Diagnosis and management of migraine in ten steps. Nat Rev Neurol 17:501\u2013514","journal-title":"Nat Rev Neurol"},{"key":"1834_CR18","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1017\/S031716710001516X","volume":"39","author":"T Pringsheim","year":"2012","unstructured":"Pringsheim T, Davenport W, Mackie G, Worthington I, Aube M, Christie SN et al (2012) Canadian Headache Society guideline for migraine prophylaxis. Can J Neurol Sci 39:S1\u201359","journal-title":"Can J Neurol Sci"},{"key":"1834_CR19","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/head.14153","volume":"61","author":"J Ailani","year":"2021","unstructured":"Ailani J, Burch RC, Robbins MS (2021) The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache 61:1021\u20131039","journal-title":"Headache"},{"key":"1834_CR20","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1111\/head.12774","volume":"56","author":"DW Dodick","year":"2016","unstructured":"Dodick DW, Loder EW, Manack Adams A, Buse DC, Fanning KM, Reed ML et al (2016) Assessing barriers to chronic migraine consultation, diagnosis, and treatment: results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) study. Headache 56:821\u2013834","journal-title":"Headache"},{"key":"1834_CR21","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1526-4610.2012.02265.x","volume":"53","author":"RB Lipton","year":"2013","unstructured":"Lipton RB, Serrano D, Holland S, Fanning KM, Reed ML, Buse DC (2013) Barriers to the diagnosis and treatment of migraine: effects of sex, income, and headache features. Headache 53:81\u201392","journal-title":"Headache"},{"key":"1834_CR22","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1046\/j.1526-4610.1998.3802087.x","volume":"38","author":"RB Lipton","year":"1998","unstructured":"Lipton RB, Stewart WF, Simon D (1998) Medical consultation for migraine: results from the American Migraine Study. Headache 38:87\u201396","journal-title":"Headache"},{"key":"1834_CR23","doi-asserted-by":"publisher","first-page":"4589","DOI":"10.1038\/s41598-022-08716-w","volume":"12","author":"M Groth","year":"2022","unstructured":"Groth M, Katsarava Z, Ehrlich M (2022) Results of the gErman migraine PatIent survey on medical care and prOPhylactic treatment experience (EPISCOPE). Sci Rep 12:4589","journal-title":"Sci Rep"},{"key":"1834_CR24","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s10194-011-0356-y","volume":"12","author":"C Andr\u00e9e","year":"2011","unstructured":"Andr\u00e9e C, Stovner LJ, Steiner TJ, Barr\u00e9 J, Katsarava Z, Lainez JM et al (2011) The Eurolight project: the impact of primary headache disorders in Europe. Description of methods. J Headache Pain 12:541\u2013549","journal-title":"J Headache Pain"},{"key":"1834_CR25","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1111\/j.1526-4610.2006.00430.x","volume":"46","author":"C Lucas","year":"2006","unstructured":"Lucas C, G\u00e9raud G, Valade D, Chautard MH, Lant\u00e9ri-Minet M (2006) Recognition and therapeutic management of migraine in 2004, in France: results of FRAMIG 3, a French nationwide population-based survey. Headache 46:715\u2013725","journal-title":"Headache"},{"key":"1834_CR26","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s10194-023-01553-w","volume":"24","author":"TP Do","year":"2023","unstructured":"Do TP, D\u00f8mgaard M, Stefansen S, Steiner TJ, Ashina M (2023) Characterizing healthcare utilization patterns in a Danish population with headache: results from the nationwide headache in Denmark (HINDER) panel. J Headache Pain 24:18","journal-title":"J Headache Pain"},{"key":"1834_CR27","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s40120-023-00456-x","volume":"12","author":"E Gross","year":"2023","unstructured":"Gross E, de la Ruiz E, Martelletti P (2023) The migraine stigma kaleidoscope view. Neurol Ther 12:703\u2013709","journal-title":"Neurol Ther"},{"key":"1834_CR28","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1037\/0003-066X.59.7.614","volume":"59","author":"P Corrigan","year":"2004","unstructured":"Corrigan P (2004) How stigma interferes with mental health care. Am Psychol 59:614\u2013625","journal-title":"Am Psychol"},{"key":"1834_CR29","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1111\/head.14401","volume":"62","author":"EK Seng","year":"2022","unstructured":"Seng EK, Shapiro RE, Buse DC, Robbins MS, Lipton RB, Parker A (2022) The unique role of stigma in migraine-related disability and quality of life. Headache 62:1354\u20131364","journal-title":"Headache"},{"key":"1834_CR30","doi-asserted-by":"publisher","first-page":"e208074","DOI":"10.1212\/WNL.0000000000208074","volume":"102","author":"RE Shapiro","year":"2024","unstructured":"Shapiro RE, Nicholson RA, Seng EK, Buse DC, Reed ML, Zagar AJ et al (2024) Migraine-related stigma and its relationship to disability, interictal burden, and quality of life: results of the OVERCOME (US) study. Neurology 102:e208074","journal-title":"Neurology"},{"key":"1834_CR31","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s10194-023-01575-4","volume":"24","author":"M Waliszewska-Pros\u00f3\u0142","year":"2023","unstructured":"Waliszewska-Pros\u00f3\u0142 M, Straburzy\u0144ski M, Czapi\u0144ska-Ciepiela EK, Nowaczewska M, Gryglas-Dworak A, Budrewicz S (2023) Migraine symptoms, healthcare resources utilization and disease burden in a large Polish migraine cohort: results from Migraine in Poland\u2014a nationwide cross-sectional survey. J Headache Pain 24:40","journal-title":"J Headache Pain"},{"key":"1834_CR32","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1001\/archinte.1992.00400180125021","volume":"152","author":"RB Lipton","year":"1992","unstructured":"Lipton RB, Stewart WF, Celentano DD, Reed ML (1992) Undiagnosed migraine headaches. A comparison of symptom-based and reported physician diagnosis. Arch Intern Med 152:1273\u20131278","journal-title":"Arch Intern Med"},{"key":"1834_CR33","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1212\/01.wnl.0000323925.29520.e7","volume":"71","author":"ME Bigal","year":"2008","unstructured":"Bigal ME, Serrano D, Reed M, Lipton RB (2008) Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology 71:559\u2013566","journal-title":"Neurology"},{"key":"1834_CR34","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s10194-018-0839-1","volume":"19","author":"Z Katsarava","year":"2018","unstructured":"Katsarava Z, Mania M, Lampl C, Herberhold J, Steiner TJ (2018) Poor medical care for people with migraine in Europe - evidence from the Eurolight study. J Headache Pain 19:10","journal-title":"J Headache Pain"},{"key":"1834_CR35","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1111\/head.13498","volume":"59","author":"C Mansfield","year":"2019","unstructured":"Mansfield C, Gebben DJ, Sutphin J, Tepper SJ, Schwedt TJ, Sapra S et al (2019) Patient preferences for preventive migraine treatments: a discrete-choice experiment. Headache 59:715\u2013726","journal-title":"Headache"},{"key":"1834_CR36","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1212\/WNL.44.11.2215-b","volume":"44","author":"RB Lipton","year":"1994","unstructured":"Lipton RB, Amatniek JC, Ferrari MD, Gross M (1994) Migraine. Identifying and removing barriers to care. Neurology 44:S63\u201368","journal-title":"Neurology"},{"key":"1834_CR37","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1212\/01.WNL.0000078940.53438.83","volume":"61","author":"RB Lipton","year":"2003","unstructured":"Lipton RB, Dodick D, Sadovsky R, Kolodner K, Endicott J, Hettiarachchi J et al (2003) A self-administered screener for migraine in primary care: the ID Migraine validation study. Neurology 61:375\u2013382","journal-title":"Neurology"},{"key":"1834_CR38","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1177\/0333102415583982","volume":"36","author":"RB Lipton","year":"2016","unstructured":"Lipton RB, Serrano D, Buse DC, Pavlovic JM, Blumenfeld AM, Dodick DW et al (2016) Improving the detection of chronic migraine: development and validation of Identify Chronic Migraine (ID-CM). Cephalalgia 36:203\u2013215","journal-title":"Cephalalgia"},{"key":"1834_CR39","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1177\/0333102418825373","volume":"39","author":"JM Pavlovic","year":"2019","unstructured":"Pavlovic JM, Yu JS, Silberstein SD, Reed ML, Kawahara SH, Cowan RP et al (2019) Development of a claims-based algorithm to identify potentially undiagnosed chronic migraine patients. Cephalalgia 39:465\u2013476","journal-title":"Cephalalgia"},{"key":"1834_CR40","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1111\/head.14520","volume":"63","author":"RB Lipton","year":"2023","unstructured":"Lipton RB, Sico J, Seng EK (2023) Migraine screening in English and Spanish. Headache 63:843\u2013845","journal-title":"Headache"},{"key":"1834_CR41","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.3390\/jcm10061191","volume":"10","author":"JH Lim","year":"2021","unstructured":"Lim JH, Karimi L, Wijeratne T (2021) An evaluation of medication prescribing patterns for acute migraine in the emergency department: a scoping review. J Clin Med 10:1191","journal-title":"J Clin Med"},{"key":"1834_CR42","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1111\/head.13717","volume":"60","author":"MT Minen","year":"2020","unstructured":"Minen MT, Zhou K, Miller L (2020) A brief look at urgent care visits for migraine: the care received and ideas to guide migraine care in this proliferating medical setting. Headache 60:542\u2013552","journal-title":"Headache"},{"key":"1834_CR43","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1001\/archneur.55.2.210","volume":"55","author":"RB Lipton","year":"1998","unstructured":"Lipton RB, Stewart WF, Ryan RE Jr., Saper J, Silberstein S, Sheftell F (1998) Efficacy and safety of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain: three double-blind, randomized, placebo-controlled trials. Arch Neurol 55:210\u2013217","journal-title":"Arch Neurol"},{"key":"1834_CR44","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/WCO.0000000000001249","volume":"37","author":"A Charles","year":"2024","unstructured":"Charles A (2024) The role of caffeine in headache disorders. Curr Opin Neurol 37:289\u2013294","journal-title":"Curr Opin Neurol"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-024-01834-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-024-01834-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-024-01834-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T09:02:53Z","timestamp":1724058173000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-024-01834-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,19]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1834"],"URL":"https:\/\/doi.org\/10.1186\/s10194-024-01834-y","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,19]]},"assertion":[{"value":"6 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Prior to participant recruitment, the study design was reviewed and approved by a central institutional review board or ethics committee for all countries included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"ML-M, reports personal fees for advisory boards, speaker panels, or investigation studies from Allergan, Amgen, Astellas, ATI, BMS, Boehringer, Boston Scientific, CoLucid, Convergence, GlaxoSmithKline, Grunenthal, IPSEN, Lundbeck, Lilly, Medtronic, Menarini, MSD, Novartis, Orion, Pfizer, Reckitt Benckiser, Saint-Jude, Sanofi-Aventis, Teva, UCB, UPSA, and Zambon.\u00a0EL has received speaker fees and consulting fees from Allergan, Eli Lilly, and Teva Neuroscience; consulting fees from Aralez Pharmaceuticals, McKesson Canada, and Medscape; speaking fees, consulting, and reimbursement for travel from Novartis; and reimbursement for travel from I-GPAC.\u00a0ZK has been a speaker and\/or consultant and\/or has received research support from Allergan, Amgen\/Novartis, Eli Lilly, Merck, and Teva.\u00a0RBL reports support for the present study from AbbVie, research support paid to his institution from the Czap Foundation, the National Headache Foundation, the National Institutes of Health, the S&L Marx Foundation, and the US Food and Drug Administration, and personal fees from AbbVie\/Allergan, American Academy of Neurology, American Headache Society, Amgen, Biohaven, BioVision, Boston, Dr. Reddy\u2019s (Promius), electroCore, Eli Lilly, GlaxoSmithKline, Grifols, Lundbeck (Alder), Merck, Pernix, Pfizer, Teva, Vector, and Vedanta Research. He holds stock\/options in Axon, Biohaven, and Manistee. He is the overall principal investigator for the CaMEO-I Study.\u00a0FS is a consultant, speaker, or scientific advisor for Amgen, Eli Lilly, Otsuka, and Teva, and the national principal investigator in Japan for the CaMEO-I Study.\u00a0MM serves on the advisory board for Abbott, AbbVie, Eli Lilly, Lundbeck, Pfizer, Salvia, and Teva; has received payment for the development of educational presentations from AbbVie, Eli Lilly, Lundbeck, Pfizer, and Teva; and is the national principal investigator in the United Kingdom for the CaMEO-I Study.\u00a0KF is managing director of MIST Research which has received research funding from AbbVie, Allay Lamp, Juva Health, NYC Langone Health and GlaxoSmithKline via grants to the National Headache Foundation.\u00a0AMA and MS are employees of AbbVie and may hold AbbVie stock.\u00a0KS was an employee of AbbVie at the time this study was conducted and may hold AbbVie stock.\u00a0DCB has received grant support and honoraria from AbbVie, Amgen, Biohaven, Collegium, Eli Lilly and Company, Lundbeck, and Teva and for work on the editorial board of <i>Current Pain and Headache Reports<\/i> and is the national principal investigator in the United States for the CaMEO-I Study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"134"}}